; and (C) to evaluate operating characteristics for Federal adverse drug event monitoring systems and expand capabilities to identify genetic associations in adverse events. 4. Adverse drug event and pharmacogenomic testing education for health care professionals The Secretary shall issue guidance for health care providers and health care leaders, including administrators, primary and specialty care physicians, pharmacists, nurse practitioners, physician assistants, physician medical geneticists, laboratory medical geneticists, genetic counselors, medical educators, and the faculty of schools of medicine and other schools of health professions, on the following: (1) Pharmacogenomic testing and the extent of its ability to prevent adverse drug reactions. (2) Pharmacogenomic testing, drug interaction alerting systems, when to refer to or consult with a genetics provider, and the applicable Federal standards of care for patients who are suspected or known to have a genetic variant that is known to impact drug metabolism or adverse reactions. (3) Evidence-based information that would encourage individuals and their health care professionals to consider pharmacogenomic testing as part of their health care plan to the extent appropriate. (4) The role of medical professionals who specialize in genetics and genomics. (5) How to incorporate pharmacogenomics into comprehensive medication management. (6) The importance of reporting information about known and relevant pharmacogenomic information when reporting adverse drug events to the FDA Adverse Event Reporting System. 5. Improving EHR systems to improve the use of pharmacogenomic information (a) Certification criteria The Secretary shall provide guidance for health care providers and health care leaders, including administrators, primary and specialty care physicians, pharmacists, nurse practitioners, physician assistants, physician medical geneticists, laboratory medical geneticists, genetic counselors, medical educators, and the faculty of schools of medicine and